Danaher (DHR) Tops Q2 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
KeyBanc Remains Positive on Life Sciences as 'Strong' Earning Season Begins with Danaher (DHR) Report
July 21, 2022 11:40 AM EDTKeyBanc analyst Paul Knight comments "Bioprocess market leaders Sartorius (SRT3) and Danaher (DHR) published 2Q22 results this morning with strong revenue and EPS beats, providing a positive backdrop for the industry at large. Results clearly indicate bioprocess companies are witnessing high-levels of demand, making up for the headwinds posed... More
UBS on Danaher (DHR): 'we believe the CPHD platform will continue to see traction as COVID-19 becomes endemic'
July 21, 2022 11:24 AM EDTUBS analyst Elizabeth Garcia reiterated a Buy rating and $297.00 price target on Danaher (NYSE: DHR).
The analyst comments "DHR kicked off 2Q22 life sciences tools earnings and reported a 2Q beat driven by the base business (+8% vs. +MSD% guidance) and COVID (+1.5% vs. -LSD... More
Cowen Reiterates Outperform Rating on Danaher (DHR), 'We expect the stock to react favorably'
July 21, 2022 10:22 AM EDTCowen analyst Dan Brennan reiterated an Outperform rating and $343.00 price target on Danaher (NYSE: DHR).
The analyst comments "Total organic growth of 9.5% well ahead of 'LSD%' guide and our 1.8%, with organic growth ex COVID testing ('base growth') of 8.0% ahead of our 4.3%.... More
Stifel Reiterates Hold Rating on Danaher (DHR), 'we are impressed with the company's ability to perform'
July 21, 2022 10:21 AM EDTStifel analyst Daniel Arias reiterated a Hold rating and {REMOVEPT} price target on Danaher (NYSE: DHR).
The analyst comments "Danaher reported 2Q22 revenues of $7.75B (+7.5% y/y), which was above Stifel ($7.12B) and consensus ($7.31B). Core revenue growth of 9.5% was ahead of expectations on... More
